AIA Group Ltd Purchases 467 Shares of Eli Lilly and Company (NYSE:LLY)

AIA Group Ltd increased its position in Eli Lilly and Company (NYSE:LLY) by 2.7% during the fourth quarter, Holdings Channel reports. The firm owned 17,719 shares of the company’s stock after buying an additional 467 shares during the quarter. AIA Group Ltd’s holdings in Eli Lilly and Company were worth $10,329,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds also recently modified their holdings of the company. Lipe & Dalton bought a new stake in shares of Eli Lilly and Company in the 4th quarter valued at about $26,000. Thompson Investment Management Inc. bought a new stake in shares of Eli Lilly and Company in the 3rd quarter valued at about $27,000. Retirement Group LLC raised its holdings in shares of Eli Lilly and Company by 159.1% in the 2nd quarter. Retirement Group LLC now owns 57 shares of the company’s stock valued at $27,000 after purchasing an additional 35 shares during the period. Legacy Financial Group LLC bought a new stake in shares of Eli Lilly and Company in the 3rd quarter valued at about $35,000. Finally, Optiver Holding B.V. acquired a new position in Eli Lilly and Company in the 3rd quarter valued at about $36,000. 82.53% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of brokerages recently commented on LLY. Erste Group Bank upgraded shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a research note on Wednesday, April 3rd. Morgan Stanley upped their price target on shares of Eli Lilly and Company from $805.00 to $950.00 and gave the company an “overweight” rating in a research note on Friday, February 16th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $815.00 price target on shares of Eli Lilly and Company in a research note on Monday. Truist Financial reiterated a “buy” rating and issued a $850.00 price target on shares of Eli Lilly and Company in a research note on Friday, March 22nd. Finally, Citigroup upped their price target on shares of Eli Lilly and Company from $675.00 to $895.00 and gave the company a “buy” rating in a research note on Tuesday, April 2nd. Three research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $728.05.

Insider Activity at Eli Lilly and Company

In related news, major shareholder Lilly Endowment Inc sold 78,573 shares of the stock in a transaction that occurred on Wednesday, January 31st. The shares were sold at an average price of $648.07, for a total value of $50,920,804.11. Following the completion of the transaction, the insider now owns 99,333,810 shares of the company’s stock, valued at approximately $64,375,262,246.70. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. 0.13% of the stock is owned by insiders.

Eli Lilly and Company Price Performance

NYSE:LLY traded down $5.95 on Thursday, hitting $744.82. The company had a trading volume of 1,123,707 shares, compared to its average volume of 3,059,505. The stock has a market capitalization of $707.70 billion, a price-to-earnings ratio of 129.32, a PEG ratio of 1.63 and a beta of 0.34. The company has a current ratio of 0.94, a quick ratio of 0.73 and a debt-to-equity ratio of 1.69. The firm has a 50 day moving average of $764.03 and a two-hundred day moving average of $657.67. Eli Lilly and Company has a 52 week low of $367.35 and a 52 week high of $800.78.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings data on Tuesday, February 6th. The company reported $2.49 EPS for the quarter, beating the consensus estimate of $2.30 by $0.19. The business had revenue of $9.35 billion during the quarter, compared to the consensus estimate of $8.95 billion. Eli Lilly and Company had a net margin of 15.36% and a return on equity of 51.22%. The firm’s revenue was up 28.1% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $2.09 EPS. On average, research analysts anticipate that Eli Lilly and Company will post 12.52 earnings per share for the current year.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.